This summary highlights key events in the health sector, including the mixed results of Gilead's Trodelvy in cancer trials, ...
Moderna said Friday that the Food and Drug Administration has approved its vaccine for respiratory syncytial virus, or RSV, ...
The RSV shot — the first ever drug using mRNA technology approved for a disease other than COVID — gives it another ...
This health news summary spotlights major developments in cancer treatments, regulatory actions on biotechnology, and the ...
The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on ...
The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA) for respiratory syncytial virus (RSV) for people ages 60 and ...
The Food and Drug Administration approved Moderna's RSV vaccine to prevent lower respiratory tract disease in adults aged 60 or older ...
ASCO Annual Meeting kicks off today, showcasing the latest research in cancer therapies to scientists and physicians.
Pfizer (PFE) stock gains as lung cancer therapy, Lorbrena, shows promising results in reducing disease progression or death ...
has recommended granting conditional marketing authorization in the EU to Pfizer's hemophilia B gene therapy Durveqtix (fidanacogene elaparvovec). Durveqtix, which is branded as Beqvez in the US and ...
Ultragenyx Pharmaceutical Inc. anticipates a meeting later this year with the U.S. FDA to discuss a BLA filing for gene therapy DTX-401 as the first potential medical treatment for glycogen storage ...
The global cell and gene therapy market is experiencing significant growth, driven by technological advancements, increasing ...